Whilst there are good reasons to believe this might be true, like all good statisticians I’m sceptical until I see some data. If the relationship indeed were different, there would be important implications for trial design and development strategy– I return to this later. Following the recent ESMO conference there are now plenty of published data. Plotted here, and identified by tumour type, are the published hazard ratios (HRs) for randomised trials with nivolumab, pembr